Arimidex Continues To Show Better Efficacy Over Tamoxifen

Published: 2004-12-10 06:55:00

Updated: 2004-12-10 06:55:00

AstraZeneca announced on December 9th the results of the ATAC (Arimidex and Tamoxifen Alone or in Combination) study presented at the 27th San Antonio Breast Cancer Symposium, which showed that Arimidex (anastrozole; an aromatase inhibitor) is better than tamoxifen in postmenopausal women diagnos...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK